FDA Puts Hold On Adaptive Trials, Wants More Clarity On Basics
Executive Summary
FDA would like to slow the escalating momentum behind adaptive clinical trial designs to allow time to craft better working definitions of the new models and build a better base before moving forward, agency officials indicated at a Pharmaceutical Research & Manufacturers of America workshop
You may also be interested in...
Adaptive Trials Could Have A Steep Regulatory Learning Curve
Sponsors should take care that drug development efficiencies gained with the advent of adaptive clinical trials aren't offset by lack of opportunity to reflect on data from one trial to the next and "design a thoughtful, complete program," FDA warns in its draft guidance for adaptive trial design
Adaptive Trials Could Have A Steep Regulatory Learning Curve
Sponsors should take care that drug development efficiencies gained with the advent of adaptive clinical trials aren't offset by lack of opportunity to reflect on data from one trial to the next and "design a thoughtful, complete program," FDA warns in its draft guidance for adaptive trial design
Adaptive Trials Could Have A Steep Regulatory Learning Curve
Sponsors should take care that drug development efficiencies gained with the advent of adaptive clinical trials aren't offset by lack of opportunity to reflect on data from one trial to the next and "design a thoughtful, complete program," FDA warns in its draft guidance for adaptive trial design